FRET based ratio-metric sensing of hyaluronidase in synthetic urine as a biomarker for bladder and prostate cancer

Rahul Chib; Sangram Raut; Rafal Fudala; Aaron Chang; Mark Mummert; Ryan Rich; Zygmunt Gryczynski; Ignacy Gryczynski

doi:10.2174/13892010113149990222

FRET based ratio-metric sensing of hyaluronidase in synthetic urine as a biomarker for bladder and prostate cancer

Rahul Chib, Sangram Raut, Rafal Fudala, Aaron Chang, Mark Mummert, Ryan Rich, Zygmunt Gryczynski, Ignacy Gryczynski

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Elevated hyaluronidase levels are found in the urine of bladder and prostate cancer patients. Therefore, HA-ase is regarded as an important biomarker for the detection of these cancers. In this report, we use a FRET based ratiometric sensing approach to detect the level of HA-ase in synthetic urine. For this, we have used a HA-FRET probe (hyaluronan) labeled with fluorescein as a donor and rhodamine as an acceptor. We monitor the digestion of our HA-FRET probe with different concentrations of HA-ase in synthetic urine via fluorescence emission. The extent to which FRET is released depends on the concentration of HA-ase. Our fluorescence intensity results are also supported with time resolved fluorescence decay data. This assay can be used to develop a non-invasive technique for the detection of bladder and/or prostate cancer progression.

Original language	English
Pages (from-to)	470-474
Number of pages	5
Journal	Current Pharmaceutical Biotechnology
Volume	14
Issue number	4
DOIs	https://doi.org/10.2174/13892010113149990222
State	Published - 2013

Keywords

Bladder cancer
HA-FRET
Hyaluronidase
Ratiometric sensing

Access to Document

10.2174/13892010113149990222

Cite this

@article{e5d97980c04544f1aa23731db76d292f,

title = "FRET based ratio-metric sensing of hyaluronidase in synthetic urine as a biomarker for bladder and prostate cancer",

abstract = "Elevated hyaluronidase levels are found in the urine of bladder and prostate cancer patients. Therefore, HA-ase is regarded as an important biomarker for the detection of these cancers. In this report, we use a FRET based ratiometric sensing approach to detect the level of HA-ase in synthetic urine. For this, we have used a HA-FRET probe (hyaluronan) labeled with fluorescein as a donor and rhodamine as an acceptor. We monitor the digestion of our HA-FRET probe with different concentrations of HA-ase in synthetic urine via fluorescence emission. The extent to which FRET is released depends on the concentration of HA-ase. Our fluorescence intensity results are also supported with time resolved fluorescence decay data. This assay can be used to develop a non-invasive technique for the detection of bladder and/or prostate cancer progression.",

keywords = "Bladder cancer, HA-FRET, Hyaluronidase, Ratiometric sensing",

author = "Rahul Chib and Sangram Raut and Rafal Fudala and Aaron Chang and Mark Mummert and Ryan Rich and Zygmunt Gryczynski and Ignacy Gryczynski",

year = "2013",

doi = "10.2174/13892010113149990222",

language = "English",

volume = "14",

pages = "470--474",

journal = "Current Pharmaceutical Biotechnology",

issn = "1389-2010",

publisher = "Bentham Science Publishers B.V.",

number = "4",

}

TY - JOUR

T1 - FRET based ratio-metric sensing of hyaluronidase in synthetic urine as a biomarker for bladder and prostate cancer

AU - Chib, Rahul

AU - Raut, Sangram

AU - Fudala, Rafal

AU - Chang, Aaron

AU - Mummert, Mark

AU - Rich, Ryan

AU - Gryczynski, Zygmunt

AU - Gryczynski, Ignacy

PY - 2013

Y1 - 2013

N2 - Elevated hyaluronidase levels are found in the urine of bladder and prostate cancer patients. Therefore, HA-ase is regarded as an important biomarker for the detection of these cancers. In this report, we use a FRET based ratiometric sensing approach to detect the level of HA-ase in synthetic urine. For this, we have used a HA-FRET probe (hyaluronan) labeled with fluorescein as a donor and rhodamine as an acceptor. We monitor the digestion of our HA-FRET probe with different concentrations of HA-ase in synthetic urine via fluorescence emission. The extent to which FRET is released depends on the concentration of HA-ase. Our fluorescence intensity results are also supported with time resolved fluorescence decay data. This assay can be used to develop a non-invasive technique for the detection of bladder and/or prostate cancer progression.

AB - Elevated hyaluronidase levels are found in the urine of bladder and prostate cancer patients. Therefore, HA-ase is regarded as an important biomarker for the detection of these cancers. In this report, we use a FRET based ratiometric sensing approach to detect the level of HA-ase in synthetic urine. For this, we have used a HA-FRET probe (hyaluronan) labeled with fluorescein as a donor and rhodamine as an acceptor. We monitor the digestion of our HA-FRET probe with different concentrations of HA-ase in synthetic urine via fluorescence emission. The extent to which FRET is released depends on the concentration of HA-ase. Our fluorescence intensity results are also supported with time resolved fluorescence decay data. This assay can be used to develop a non-invasive technique for the detection of bladder and/or prostate cancer progression.

KW - Bladder cancer

KW - HA-FRET

KW - Hyaluronidase

KW - Ratiometric sensing

UR - http://www.scopus.com/inward/record.url?scp=84878786852&partnerID=8YFLogxK

U2 - 10.2174/13892010113149990222

DO - 10.2174/13892010113149990222

M3 - Article

C2 - 23360262

AN - SCOPUS:84878786852

SN - 1389-2010

VL - 14

SP - 470

EP - 474

JO - Current Pharmaceutical Biotechnology

JF - Current Pharmaceutical Biotechnology

IS - 4

ER -

FRET based ratio-metric sensing of hyaluronidase in synthetic urine as a biomarker for bladder and prostate cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this